ACHV - Achieve nabs two U.S. patents for cytisinicline in smoking cessation and prevention

Achieve Life Sciences (ACHV) announces that the USPTO has allowed Patent Application No. 16/993,522 and Patent Application No. 17/101,686 covering the novel 3.0 mg three times daily ((TID)) cytisinicline dosing regimen. The allowed claims cover this dosing regimen and administration method for the treatment of nicotine addiction and for promoting a reduction and/or cessation in smoking and vaping in treatment naïve and refractory patients who have failed previous smoking cessation treatments.Upon approval, these patents are expected to be included in the FDA's Orange Book.Once issued, the patents arising from the ‘522 and ‘686 Applications will expire in Q3 2040. Achieve is currently recruiting smokers to participate in the ORCA-2 Phase 3 trial, which is expected to complete enrollment by the mid 2021.ACHV shares up 3.3% premarket trading at $8.40.

For further details see:

Achieve nabs two U.S. patents for cytisinicline in smoking cessation and prevention